News

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...
Regeneron: Potential Entrant To Weight Loss Market
Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...
Zacks.com on MSN4d
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the ...
Zacks.com on MSN6h
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...
PMLive1d
Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...
PharmExec4d
FDA Approves Regeneron, Sanofi’s Dupixent for Bullous Pemphigoid
FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...
Wall Street Journal3d
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ - The Wall Street Journal
Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...
Stocktwits on MSN4d
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...
Fierce Biotech7h
Investors sweet on Nektar as phase 2b eczema success doubles share price
Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...
Morningstar4d
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - Morningstar
Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...